US chipmaker Nvidia invests $50M in Recursion for AI models in biotech
Aim is to speed up development of artificial intelligence models for biology, chemistry
ISTANBUL
US chipmaker Nvidia invested $50 million in Recursion Pharmaceuticals to accelerate models in artificial intelligence (AI) enabled drug discovery.
Recursion said Wednesday in a statement that it has plans to accelerate the development of its AI foundation models for biology and chemistry in collaboration with Nvidia.
The company said it also plans to optimize and distribute to biotechnology companies using Nvidia cloud services.
"Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery," said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. "With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space."
Founder and CEO of NVIDIA Jensen Huang said generative AI is a revolutionary tool to discover new medicines and treatments, adding Recursion is doing work in digital biology and chemistry with Nvidia AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.
